Dustin Chernick

Statistics

Publications

Citations

174

H-Index

Active since

2016

Affiliations

Adamas Pharmaceuticals (United States)(Current)

University of South Florida

University of Kansas Medical Center

University of Minnesota

Dustin Chernick is an author at Adamas Pharmaceuticals (United States) specializing in parkinsonian disorders, medicine, and parkinson’s disease treatment.

Publications per year

2016–2021

Publications

High‐density lipoprotein mimetic peptide 4F mitigates amyloid‐β‐induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia

Dustin Chernick, Stephanie Ortiz‐Valle, Angela Jeong et al. · Journal of Neurochemistry · 2018 · 52 citations · Full text

Life Sciences, Neurology, Neuroscience +16

Metabolic Labeling with an Alkyne-modified Isoprenoid Analog Facilitates Imaging and Quantification of the Prenylome in Cells

Charuta C. Palsuledesai, Joshua D. Ochocki, Michelle M. Kuhns et al. · ACS Chemical Biology · 2016 · 48 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease

Caroline M. Tanner, Rajesh Pahwa, Robert A. Hauser et al. · Journal of Parkinson s Disease · 2020 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease

Robert A. Hauser, Ryan R. Walsh, Rajesh Pahwa et al. · Frontiers in Neurology · 2021 · 24 citations · Full text

Medicine, Neurology, Pharmacology +17

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia

Robert A. Hauser, Shyamal H. Mehta, Daniel Kremens et al. · Neurology and Therapy · 2021 · 14 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–5 of 5